Alexion Pharmaceuticals, a biopharmaceutical company specializing in rare diseases, has announced a restructuring that will impact about 7 percent of its workforce, according to a Reuters article. As of Dec. 31, the company had 3,121 employees.
Alexion's chief executive and chief financial officer resigned in December after the board had reportedly lost confidence in them. Alexion said that CEO David Hallal resigned for personal reasons, while CFO Vikas Sinha left to pursue other opportunities.
Read the full story